Literature DB >> 12522441

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.

Terry W Hermiston1, Irene Kuhn.   

Abstract

Oncolytic viruses are attractive therapeutics for cancer because they selectively amplify, through replication and spread, the input dose of virus in the target tumor. To date, clinical trials have demonstrated marked safety but have not realized their theoretical efficacy potential. In this review, we consider the potential of armed therapeutic viruses, whose lytic potential is enhanced by genetically engineered therapeutic transgene expression from the virus, as potential vehicles to increase the potency of these agents. Several classes of therapeutic genes are outlined, and potential synergies and hurdles to their delivery from replicating viruses are discussed.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12522441     DOI： 10.1038/sj.cgt.7700542

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


  40 in total

1.  Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma.

Authors:  Qing He; Yang Liu; Qing Zou; Yong-Song Guan
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.

Authors:  Tomer Granot; Yoshihide Yamanashi; Daniel Meruelo
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

Review 3.  Fighting cancer with oncolytic viruses.

Authors:  Yuti Chernajovsky; Lorna Layward; Nicholas Lemoine
Journal:  BMJ       Date:  2006-01-21

4.  Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.

Authors:  Chien-Kuo Tai; Wei Jun Wang; Thomas C Chen; Noriyuki Kasahara
Journal:  Mol Ther       Date:  2005-11       Impact factor: 11.454

5.  Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.

Authors:  S Bossow; C Grossardt; A Temme; M F Leber; S Sawall; E P Rieber; R Cattaneo; C von Kalle; G Ungerechts
Journal:  Cancer Gene Ther       Date:  2011-06-24       Impact factor: 5.987

Review 6.  Gene therapy of liver cancer.

Authors:  Ruben Hernandez-Alcoceba; Bruno Sangro; Jesus Prieto
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

7.  Viral vectors for vaccine applications.

Authors:  Youngjoo Choi; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

8.  Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  Enhanced cellular uptake of a triplex-forming oligonucleotide by nanoparticle formation in the presence of polypropylenimine dendrimers.

Authors:  Latha M Santhakumaran; Thresia Thomas; T J Thomas
Journal:  Nucleic Acids Res       Date:  2004-04-15       Impact factor: 16.971

10.  Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer.

Authors:  J R Tysome; A Briat; G Alusi; F Cao; D Gao; J Yu; P Wang; S Yang; Z Dong; S Wang; L Deng; J Francis; T Timiryasova; I Fodor; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2009-07-09       Impact factor: 5.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.